The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis.
HIV
HIV testing, community-based HIV self-testing
benefits and cost
cost-effectiveness
mathematical modelling
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
04
05
2018
accepted:
18
01
2019
entrez:
26
3
2019
pubmed:
26
3
2019
medline:
16
7
2020
Statut:
ppublish
Résumé
The prevalence of undiagnosed HIV is declining in Africa, and various HIV testing approaches are finding lower positivity rates. In this context, the epidemiological impact and cost-effectiveness of community-based HIV self-testing (CB-HIVST) is unclear. We aimed to assess this in different sub-populations and across scenarios characterized by different adult HIV prevalence and antiretroviral treatment programmes in sub-Saharan Africa. The synthesis model was used to address this aim. Three sub-populations were considered for CB-HIVST: (i) women having transactional sex (WTS); (ii) young people (15 to 24 years); and (iii) adult men (25 to 49 years). We assumed uptake of CB-HIVST similar to that reported in epidemiological studies (base case), or assumed people use CB-HIVST only if exposed to risk (condomless sex) since last HIV test. We also considered a five-year time-limited CB-HIVST programme. Cost-effectiveness was defined by an incremental cost-effectiveness ratio (ICER; cost-per-disability-adjusted life-year (DALY) averted) below US$500 over a time horizon of 50 years. The efficiency of targeted CB-HIVST was evaluated using the number of additional tests per infection or death averted. In the base case, targeting adult men with CB-HIVST offered the greatest impact, averting 1500 HIV infections and 520 deaths per year in the context of a simulated country with nine million adults, and impact could be enhanced by linkage to voluntary medical male circumcision (VMMC). However, the approach was only cost-effective if the programme was limited to five years or the undiagnosed prevalence was above 3%. CB-HIVST to WTS was the most cost-effective. The main drivers of cost-effectiveness were the cost of CB-HIVST and the prevalence of undiagnosed HIV. All other CB-HIVST scenarios had an ICER above US$500 per DALY averted. CB-HIVST showed an important epidemiological impact. To maximize population health within a fixed budget, CB-HIVST needs to be targeted on the basis of the prevalence of undiagnosed HIV, sub-population and the overall costs of delivering this testing modality. Linkage to VMMC enhances its cost-effectiveness.
Identifiants
pubmed: 30907498
doi: 10.1002/jia2.25243
pmc: PMC6432108
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25243Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Wellcome Trust
ID : 200901/Z/16/Z
Pays : United Kingdom
Organisme : Unitaid
Pays : International
Informations de copyright
© 2019 World Health Organization; licensed by IAS.
Références
Lancet. 2012 Dec 15;380(9859):2129-43
pubmed: 23245605
Lancet HIV. 2016 Sep;3(9):e441-e448
pubmed: 27562745
AIDS Behav. 2010 Jun;14(3):708-15
pubmed: 19623481
Lancet HIV. 2017 Feb;4(2):e83-e92
pubmed: 27863998
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25243
pubmed: 30907498
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
PLoS Med. 2017 Nov 28;14(11):e1002458
pubmed: 29182634
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD001224
pubmed: 22972050
Sex Transm Infect. 2006 Jun;82 Suppl 3:iii18-25
pubmed: 16735288
Lancet. 2014 Jul 19;384(9939):249-56
pubmed: 25042235
PLoS Med. 2017 Nov 21;14(11):e1002442
pubmed: 29161260
Lancet HIV. 2018 Jun;5(6):e277-e290
pubmed: 29703707
Lancet HIV. 2018 Mar;5(3):e146-e154
pubmed: 29174084
J Infect Dis. 2015 Aug 15;212(4):570-7
pubmed: 25767214
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
Bull World Health Organ. 2014 Jul 1;92(7):499-511AD
pubmed: 25110375
AIDS Behav. 2013 Jun;17(5):1571-90
pubmed: 22752501
Lancet HIV. 2017 Oct;4(10):e457-e464
pubmed: 28801191
AIDS. 2016 Nov 28;30(18):2855-2864
pubmed: 27603290
AIDS. 2018 Mar 13;32(5):645-652
pubmed: 29494424
AIDS. 2016 Nov 13;30(17):2685-2695
pubmed: 27782965
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
J Int AIDS Soc. 2016 Feb 15;19(1):20673
pubmed: 26894388
Lancet Infect Dis. 2012 May;12(5):373-80
pubmed: 22277215
Value Health. 2016 Dec;19(8):921-928
pubmed: 27987641
AIDS Behav. 2015 Nov;19(11):1949-65
pubmed: 26054390
Clin Infect Dis. 2018 Apr 3;66(8):1211-1221
pubmed: 29136117
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
PLoS One. 2017 Oct 16;12(10):e0185740
pubmed: 29036171
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
PLoS One. 2014 Nov 12;9(11):e108304
pubmed: 25389777
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21755
pubmed: 28872271
Nature. 2015 Dec 3;528(7580):S68-76
pubmed: 26633768
J Int AIDS Soc. 2019 Jul;22(7):e25325
pubmed: 31287620